In clinical practice, AD pathology is commonly evaluated through VR of amyloid‐PET scans or analysis of CSF biomarkers, such as Aβ42, phosphorylated tau (pTau), and total tau (tTau). The gene discussed is MAPT; the disease is Alzheimer disease.